{"name":"Quark Pharmaceuticals","slug":"quark-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"Quark Pharmaceuticals is a pharmaceutical company that develops RNA interference-based treatments for chronic and acute diseases.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNa3pKNWVVQWJKa01HNnNOTm5TVDBUWWNlV2dxNE1WYUhJb01CblEzZV8xWWtUb2VmajZrOGg0Zm40NGxqVmw5bm9RV28tV2cwQ05IelFxMGlyYTdzRXJRN1UwNmFzaGJNRVJubE9UQmRLTlBHR0FVZGRGRll5Sm9wcng1OGdvZFBxelhpTFZremVYX1hyQUtSUFIzOXk?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Trends in Growth, Segment Analysis, and Competitive Strategies Influencing the Acute Kidney Injury Market - openPR.com","headline":"Trends in Growth, Segment Analysis, and Competitive Strategies Influencing the Acute Kidney Injury Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxQMHhfSGI1a3NjMkNsRC1ZdkRNUzJnS0FnMkhZbFBiRWF2Ykp0cHlVQ3IyZVRsZWNQQjNEaW5ESUd5V0ktU3NYYnI4NHAxT0tDLVFQZ0dDMlhyekNqZzI4RnRhX3FXV3VnX1VFODIwMkRvdUwxMEJqRlBjNnkwRktlODhwSEJOWEVVaERzXzlPTGdpSDNITmpFWXdjYldwUHkwWXVldjZXSkp6N3lZWC1LOEtqOGJRY05NdU52V1JFejhKX1BFS3NXRG1wd0NnckxyNmdIRWxoUGVnalJOeWp3Rl9TaDNHYThTOHc?oc=5","date":"2025-03-25","type":"pipeline","source":"PR Newswire","summary":"ROCKLATAN/ROCLANDA Strengthens Market Position with Robust Sales and Patient Outcomes | DelveInsight - PR Newswire","headline":"ROCKLATAN/ROCLANDA Strengthens Market Position with Robust Sales and Patient Outcomes | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxONzJwRzBpN1dGQ1h1QkRLdEFDQnRrcTJhMUkwSTJRdk9uZWJkVUZOd2VNel8tTWlJYzZkSzdJSG9nRXRuZFpkVFpEV1RKMDBvTWlkNnRaN3BzVUU5SWdZZDVwc1djWWhEaVhPRjlxWS15RDRJbm9hS29hQllqQktObGtUTDZ6OHlRQ2F4ZGlNQzFRUlpNakd2MkdiU244N3hLX3lka3FHS3VoTlVtbzJ2LXk2UHJ0ckZ5VjdGUi1MSUFRaU5YX2kxb2tOUnJoUFItM256NTFaaHhRSlpFRjdNVWE1eEZmY3RzdW5LZmZGcmI4dEVaNFlWcmZFQ3RXRVhfaGctMVhYTm9pdVMyaUx4ZC1feDh1SGk2czRLRUJzaDQydWVlWUdQUFR6bzJ5c09PaUtCWFNoQQ?oc=5","date":"2025-02-26","type":"pipeline","source":"GlobeNewswire","summary":"DURYSTA’s Market Potential Across the 7MM is Set to Soar - GlobeNewswire","headline":"DURYSTA’s Market Potential Across the 7MM is Set to Soar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE5waW00SXlsaF8xYTNqM2UwWHJNUnpIOVV3aTlZRGZQMVczTHZvbDFXUjBYQm5lb0FOMXVHc3BwNDAxVzZtVjlCUlVMQ0w0NmpQWE5sNTFXdVI2LVQ1bFNQWncwWDFOdVFTY2FMUi1EN2gtMWxmY3c?oc=5","date":"2019-07-16","type":"trial","source":"Labiotech.eu","summary":"Update: AM-Pharma Increases Acute Kidney Injury Phase III Funds to €163M - Labiotech.eu","headline":"Update: AM-Pharma Increases Acute Kidney Injury Phase III Funds to €163M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNcVlKQ2QtUHQ5MlJ4Q1VWdUdNaFVlcEVxMWZNMHJINHMzbXFtakVVeHhmdW1RN0VHai1pOTRDbFRpcVBVcXJ1aHptMkFMcFFldHZzcFl3YmJvRXJQSTVOOXptbFFRN21fTUdVNkozeGxDX2tFLVNRS0J6eE1kNjdjVG93?oc=5","date":"2018-12-17","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"Top 10 RNA-Based Biopharmas of 2018 - Genetic Engineering and Biotechnology News","headline":"Top 10 RNA-Based Biopharmas of 2018","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOQndZMDNyMFo1NE5xSVQySkI1Rk5sOFNxYXRRWmRFc1JCOGxnck1DczhBNWotQlE4UndqSHdXcnEybUVFZFZQNDlkeUFjbU9Dek9CQnVYZlJaVXhZMFdaT1RjeTNJSHg4ZWc4eldlcU1NZ0tSckN4YkdGZGduNWg5WTBpOUNfSm11eTBYQ0xCcmoyNjQ?oc=5","date":"2017-07-27","type":"trial","source":"Fierce Biotech","summary":"Quark RNAi drug hits endpoints in phase 2 kidney trial - Fierce Biotech","headline":"Quark RNAi drug hits endpoints in phase 2 kidney trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE4zUFJoYllEX1JCMWtxVjB0cXhVa2hZNUg0T0huNTNfbnQzZWNZQWRzQlU4Y3h2S25qSjU1VVZJb0RhYU10S2JmSW1veE1fMXQwdWU3bl9LbEJwTEJUanJuenJCMWVJX0JJSFlGWTFmMkM4V2pFV1huNA?oc=5","date":"2017-07-27","type":"trial","source":"BioPharma Dive","summary":"Quark wins in Phase 2, raising the stakes for RNAi - BioPharma Dive","headline":"Quark wins in Phase 2, raising the stakes for RNAi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPVm9IdTVHWGtvaXlRVTAxS1NNeWwxckRHWmJQZG16dWNMc0Z2dkNwOGgzSUxGN0VPaWVqRG5BLVFsUV9jcFU3a21tYnBLb3N5Q0RIckN0MVYza1Jfc1lBck1TVE55eTd1T0wwLWNQX2JjM1htVU9NakRHbHQ4a3ZjOF9LTWI2aFNhelNtQlRVMXpZS28?oc=5","date":"2017-07-06","type":"pipeline","source":"Fierce Biotech","summary":"Silence takes Alnylam to court over RNAi IP dispute - Fierce Biotech","headline":"Silence takes Alnylam to court over RNAi IP dispute","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQa2tFaDJUcVRxaWJybjJQZlU2SkRlbGIwbVZuZ3JTVVIxU3k3MXgtMHZYdzRhMGpWOEREb2xZS0xfdTE1Ympmb1ltRm9HRkgxbS1oR0JqMXlNdVhBdjA4N0syb2JJMWoyYzFlbzNqOURvcnYxbDB1Y3NZeG03bno4OVh1QlhDR19tOU83SE1HQmpOekdtZVhER3NZdzgzRkFsNE5vUjNMRzN0QVBlbEc4?oc=5","date":"2016-06-23","type":"trial","source":"Fierce Pharma","summary":"Biocon, Quark dose first randomized patient in siRNA clinical trial in India - Fierce Pharma","headline":"Biocon, Quark dose first randomized patient in siRNA clinical trial in India","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOblU4X2FPbURYSVBhS00yWUtkWWZfQ0Z6VXZDRE5IanpXazBneHlhUFk4QWpvMWtUdXBoTVRJQTNXaGl4X3pyMldjZE4wQ0YtVm1vd04wMFpjZnBrODRtWTN0M00xdGpHa1VOZjJoRXpyLTlxcXZnVXU3TGs2dThWdkMtOGZub1owYmtESXVYYmR3SnVhM1Z4TWMxYWV5VkhIelIwUDdILXl5RGR4YXE0?oc=5","date":"2016-06-23","type":"trial","source":"NDTV Profit","summary":"Biocon, Quark Get DCGI's Nod For Trials Of Eye Disease Drug - NDTV Profit","headline":"Biocon, Quark Get DCGI's Nod For Trials Of Eye Disease Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPeDRiYkJqWlpiUkt4THFmV1F5alJUdXVldlZiTWFOUzkzYzBqRjRFYzlyUG5oSzlJSnVybHJjUkc0THZLRFFfVTFHWG5OdDlCeDlJemhxVVYxZ1VUOEw5cDlMRUxib1l2YW5TcjFLVm1XUmJkMXdTUkpTV0NoN1ZqOVVkQU5KVHpwYWtpVWhtNlByel9DS0c0SU1xaU5fNms?oc=5","date":"2012-07-10","type":"pipeline","source":"European Pharmaceutical Review","summary":"Ten years of siRNA – a clinical overview - European Pharmaceutical Review","headline":"Ten years of siRNA – a clinical overview","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}